Table 5.
SII ≤1835 (n = 81) |
SII >1835 (n = 38) |
p-Value | |
---|---|---|---|
Age (Years) | 71 (58–80) | 74 (62–80) | 0.57 |
Gender (F/M) | 32/49 | 10/28 | 0.16 |
Smoking status (No/Yes/Former) | 48/25/8 | 19/11/8 | 0.24 |
BMI (Non-Obese/Obese) | 62/19 | 30/8 | 0.77 |
P/F Ratio | 301 ± 85 | 226 ± 79 | <0.001 |
Chest CT Severity Score | 9.0 (5.0–14.0) | 21.0 (13.3–23.0) | <0.001 |
Intensity of Care (No, OT, RSni, RSi) | 16/39/12/14 | 9/11/10/8 | 0.21 |
Interval between Disease Onset and Admission (Days) | 6.0 (3.0–8.0) | 6.0 (3.0–8.8) | 0.99 |
Hospital Stay (Days) | 17 (11–26) | 14 (6–27) | 0.29 |
Survivors (No/Yes) | 13/68 | 16/22 | 0.002 |
Charlson Comorbidity Index | 4.0 (2.0–6.3) | 4.5 (2.0–7.0) | 0.23 |
Cardiovascular Disease (No/Yes) | 35/46 | 15/23 | 0.7 |
Respiratory Disease (No/Yes) | 67/14 | 26/12 | 0.08 |
Kidney Disease (No/Yes) | 69/12 | 33/5 | 0.81 |
Diabetes (No/Yes) | 62/19 | 32/6 | 0.34 |
Cancer (No/Yes) | 70/11 | 31/7 | 0.49 |
Autoimmunity (No/Yes) | 77/4 | 36/2 | 0.94 |
ACE inhibitors (No/Yes) | 64/17 | 32/6 | 0.51 |
ARBs (No/Yes) | 65/16 | 31/7 | 0.86 |
WBC (×109 L) | 5.90 (4.81–7.87) | 9.90 (7.49–12.60) | <0.001 |
Monocytes (×109 L) | 0.39 (0.20–0.50) | 0.30 (0.28–0.50) | 0.77 |
Lymphocytes (×109 L) | 1.00 (0.80–1.35) | 0.64 (0.50–0.80) | <0.001 |
Neutrophils (×109 L) | 4.40 (3.40–5.55) | 8.65 (6.00–11.60) | <0.001 |
Platelets (×109 L) | 183 (147–233) | 267 (220–361) | <0.001 |
RDW (%) | 15.4 (14.2–16.6) | 14.9 (13.7–16.0) | 0.14 |
MPV (fL) | 8.45 (8.20–9.00) | 8.45 (7.9–8.9) | 0.38 |
ACE: angiotensin converting enzyme; ARBs: angiotensin II receptor blockers; BMI: body mass index; COVID-19: coronavirus disease 2019; F: female; M: male; MPV, mean platelet volume; OT: oxygen therapy; P/F: PaO2/FiO2; RDW, red blood cell distribution width; RSi: invasive respiratory support; RSni: non-invasive respiratory support; WBC: white blood cells. All continuous variables are reported as medians and interquartile ranges. Statistical significance set at 0.05. All statistically significant values are reported in bold.